| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
-secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome
,1
* Department of Psychiatry, Brain Research Center,
Graduate Program in Neuroscience, The University of British Columbia, Vancouver, British Columbia, Canada; and
# Department of Human Anatomy, Chongqing University of Medical Sciences, Chongqing, China
1 Correspondence: Department of Psychiatry, The University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada. E-mail: weihong{at}interchange.ubc.ca
Amyloid ß protein (Aß), the major component of neuritic plaques in Alzheimer’s disease (AD), is derived from APP by sequential cleavages of ß- and 
-secretases. Beta-site APP cleaving enzyme 1 (BACE1) is the major ß-secretase in vivo. Beta-site APP cleaving enzyme 2 (BACE2) is the homologue of BACE1. The majority of people with Down syndrome (DS), also called Trisomy 21 syndrome, will develop AD neuropathology after middle age. We and others have shown that APP C99, the major ß-secretase product, and Aß are markedly increased in DS. Since BACE2 is located on chromosome 21, it is speculated that BACE2 may play a role in AD pathogenesis in DS. In this report we found that BACE2 cleaves APP at a novel 
site downstream of the 
site, abolishing Aß production. Overexpression of BACE2 by lentivirus markedly reduced Aß production in primary neurons derived from Swedish mutant APP transgenic mice. Despite an extra copy of the BACE2 gene in DS and the increase of its transcription, BACE2 protein levels are unchanged. Our data clearly demonstrate that BACE2, as a novel -secretase to cleave APP within the Aß domain, is not involved in the AD pathogenesis of DS patients; instead, therapeutic interventions that potentiate BACE2 may prevent AD pathogenesis.—Sun, X., He, G., Song, W. BACE2, as a novel APP -secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome.
Key Words: BACE2 • -secretase • Alzheimer • Down syndrome • Trisomy 21
This article has been cited by other articles:
|
|
 |
|
  H. Liu, P. Wang, W. Song, and X. Sun Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways FASEB J, October 1, 2009; 23(10): 3383 - 3392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qing, G. He, P. T. T. Ly, C. J. Fox, M. Staufenbiel, F. Cai, Z. Zhang, S. Wei, X. Sun, C.-H. Chen, et al. Valproic acid inhibits A{beta} production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models J. Exp. Med., November 24, 2008; 205(12): 2781 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Tansley, B. L. Burgess, M. T. Bryan, Y. Su, V. Hirsch-Reinshagen, J. Pearce, J. Y. Chan, A. Wilkinson, J. Evans, K. E. Naus, et al. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of {beta}-amyloid precursor protein J. Lipid Res., May 1, 2007; 48(5): 1022 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Sun, G. He, H. Qing, W. Zhou, F. Dobie, F. Cai, M. Staufenbiel, L. E. Huang, and W. Song Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression PNAS, December 5, 2006; 103(49): 18727 - 18732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Sun, Y. Tong, H. Qing, C.-H. Chen, and W. Song Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome FASEB J, July 1, 2006; 20(9): 1361 - 1368. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
